N@N

CSL share price on watch amid $2.1b half year profit and dividend hike

CSL, a global biotechnology company, reported a significant financial performance in its half-year results, with a statutory net profit after tax of $US1.9 billion, up 13% from the previous year, and an underlying profit of $US2.1 billion, marking a 20% increase. This performance was driven by strong demand for its immunoglobulin therapies and robust growth in its plasma collections. CSL also announced a 10% increase in its interim dividend to $US1.19 per share, reflecting confidence in its financial health and future prospects. Despite these positive outcomes, CSL's share price experienced a slight decline of 0.5% to $277.75, possibly due to concerns over the company's outlook for the full year, which was described as "cautiously optimistic" due to potential impacts from currency fluctuations and geopolitical tensions. The company's CEO, Paul Perreault, highlighted the ongoing recovery in plasma collections and the successful launch of new products as key drivers for future growth.

Read the Full MSN Article at:
[ https://www.msn.com/en-au/money/economy/csl-share-price-on-watch-amid-2-1b-half-year-profit-and-dividend-hike/ar-AA1yM2wc ]